试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-25
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
编号:NCT03498222登记状态:入组前撤回企业 / 申办者:Queen Mary University of London
药物 / 成分:Atezolizumab、Pemetrexed、Carboplatin、ADI PEG20
登记的停止原因(原文):Funder and IMP manufacturer withdrew support
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-24
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
编号:NCT00693342登记状态:入组前撤回企业 / 申办者:Gynecologic Oncology Group
药物 / 成分:immunological adjuvant OPT-821、polyvalent antigen-KLH conjugate vaccine
登记的停止原因(原文):Never opened to accrual, a GOG working number, not developed into a clinical trial.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.
编号:NCT02223299登记状态:入组前撤回企业 / 申办者:John D. Dingell VA Medical Center
药物 / 成分:L-tyrosine、L-Tryptophan、deplin、Placebo A
登记的停止原因(原文):The study was never approved by the IRB and the PI left the VA
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery
编号:NCT02970097登记状态:入组前撤回企业 / 申办者:University of Pennsylvania
药物 / 成分:20ml bolus of 0.5% ropivicaine、10 ml of 0.5% ropivicaine、Midazolam、Fentanyl
登记的停止原因(原文):lack of resources
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
编号:NCT03328936登记状态:入组前撤回企业 / 申办者:Ohio State University Comprehensive Cancer Center
药物 / 成分:Laboratory Biomarker Analysis、Melphalan Hydrochloride、Melphalan Hydrochloride、Pharmacological Study
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation
编号:NCT03610282登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:IV Methylphenidate、Propofol
登记的停止原因(原文):We have decided to withdraw the study prior to enrollment of the first participant in order to pursue other research studies.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
编号:NCT04041362登记状态:入组前撤回企业 / 申办者:United BioPharma
药物 / 成分:UB-421、Antiretroviral Therapy (ART)
登记的停止原因(原文):The study will not be submitted to authority for IND application.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
编号:NCT04279938登记状态:入组前撤回企业 / 申办者:Royal Marsden NHS Foundation Trust
药物 / 成分:Tinostamustinein、Pembrolizumab、Rituximab
登记的停止原因(原文):Safety data on drug
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-20
Effect of Simvastatin Withdrawal on Ocular Endothelial Function
编号:NCT02533141登记状态:入组前撤回企业 / 申办者:Medical University of Vienna
药物 / 成分:Dynamic Vessel Analyzer (DVA)、Laser Doppler Velocimetry (LDV)、Simvastatin、Placebo
登记的停止原因(原文):no funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-02-19
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
编号:NCT00308204登记状态:入组前撤回企业 / 申办者:The Cleveland Clinic
药物 / 成分:Raptiva
登记的停止原因(原文):inadequate number of enrolled study subjects
查看官方原始记录 ↗